Feature | January 22, 2007 | Amy Ballard, MEd

Shedding New Light On Ovarian Cancer

Fluorescent imaging illuminates as little as 0.3 mm.

Over the last 30 years, the mortality rate associated with ovarian cancer has only slightly decreased despite multiple efforts aimed at developing an effective method for its early detection, such as transvaginal ultrasound to visualize ovaries, measuring CA-125 levels and evaluating protein tumor-marker panels. In the U.S., approximately 16,210 women die from ovarian cancer every year and nearly 23,400 women are diagnosed annually, rendering it the most deadly gynecological disease.
The high death rate is attributable to the fact that 75 percent of diagnoses are made after the cancer has metastasized to other organs. Most women are diagnosed with advanced stage III or IV disease, and only 15 percent of these women survive for five years. Women who are diagnosed with stage I or II ovarian cancer have a 94 percent chance of a five-year survival. Clearly, establishing effective detection, staging and treatment methods are essential to combating this disease.
Despite the low success rate of early detection, researchers are optimistic that they will be able to reduce mortality rates using optical imaging in resecting tumors. Many times during debulking, small tumor implants are not detected in the peritoneal cavity and mesentery. The ability to accurately locate small tumor microfoci during surgery could improve tumor resection, which would better prevent intraperitoneal metastases. Avidin-FITC, a fluorescent imaging agent that binds to proteins expressed on the surface of many cancer cells, has been evaluated for its efficacy in allowing visualization of submillimeter tumor implants.
Image-guided conventional fluorescent imaging using the Maestro In Vivo Imaging System and the FLA-5100 from Fuji visualize implants as small as 0.3 mm. Once in-vivo fluorescent images were visualized with Maestro, in order to validate the size and tumor type of the in vivo images detected, the implants visualized were excised and examined using Fuji’s FLA-5100, which confirmed the size and tumor type. The test also showed that multiple lesions, all containing cancer cells, were visualized in vivo as small as 0.3 mm and the minimum detectable size was 0.1 mm. There were no false positives. Researchers expect that with optimal tumor resection, patients will respond more favorably to adjuvant therapies.

Related Content

VolparaDensity With Tyrer-Cuzick Model Improves Breast Cancer Risk Stratification
News | Breast Density | May 22, 2019
Research has demonstrated use of Volpara Solutions' VolparaDensity software in combination with the Tyrer-Cuzick Breast...
Partial Breast Irradiation Effective, Convenient Treatment Option for Low-Risk Breast Cancer
News | Radiation Therapy | May 20, 2019
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast...
Managing Architectural Distortion on Mammography Based on MR Enhancement
News | Mammography | May 15, 2019
High negative predictive values (NPV) in mammography architectural distortion (AD) without ultrasonographic (US)...
Screening MRI Detects BI-RADS 3 Breast Cancer in High-risk Patients
News | MRI Breast | May 09, 2019
When appropriate, short-interval follow-up magnetic resonance imaging (MRI) can be used to identify early-stage breast...
Novel Artificial Intelligence Method Predicts Future Risk of Breast Cancer
News | Artificial Intelligence | May 08, 2019
Researchers from two major institutions have developed a new tool with advanced artificial intelligence (AI) methods to...
Georgia Becomes 38th State With Breast Density Inform Law
News | Breast Density | May 06, 2019
Georgia Gov. Brian Kemp signed breast density inform bill HB62 into law May 3, 2019. The law, which becomes effective...
American Society of Breast Surgeons Issues Risk-based Screening Mammography Guidelines
News | Mammography | May 03, 2019
The American Society of Breast Surgeons (ASBrS) has released the first screening mammography guidelines based on a...
Hologic Launches Trident HD Specimen Radiography System
Technology | Breast Biopsy Systems | April 26, 2019
Hologic Inc. announced global commercial availability of the Trident HD specimen radiography system. The next-...
California Protons Cancer Therapy Center Begins Breast Cancer Study Enrollment
News | Proton Therapy | April 25, 2019
California Protons Cancer Therapy Center announced two major efforts representing significant steps forward in breast...
Women With Coronary Artery Wall Thickness at Risk for Heart Disease
News | Cardiac Imaging | April 25, 2019
The thickness of the coronary artery wall as measured by magnetic resonance imaging (MRI) is an independent marker for...